GLP-1 Advisor | One Day MD

By Dr. Frank Yap, MD · One Day Media Network · Published October 16, 2026 · Last updated October 16, 2026 ·  Quick Answer A fake GLP-1 is any semaglutide or tirzepatide product that is counterfeit, mislabeled, unapproved or sold as “research use only.” Regulators have found pens with genuine lot numbers but fake labels, oral “GLP-1” liquids containing no GLP-1 at all, and compounded products marketed as “the same as Ozempic.” The safest rule: obtain GLP-1 medicines only through a licensed prescriber and a regulated pharmacy, never through chat apps, “agents” or marketplaces. Disclosure. Medical education, not individual medical advice. This page recommends no product and contains no affiliate links. One Day Media Network participates in affiliate programs on other pages. On this page What counts as a fake GLP-1 What regulators have documented Compounded is not generic How to check an offer If you already used a grey-market pen A single decision rule Where to report Using t...

Home › GLP-1 Hub By Dr. Frank Yap, MD  |  Last updated: October 2026  |  Purpose: evidence and safety education, not individual medical advice Quick Answer GLP-1 therapy now includes injections and, since 2025–2026, two FDA-approved pills : oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron) , approved April 1, 2026 as the first non-peptide oral GLP-1 for weight management. Retatrutide is not approved anywhere ; it remains in Phase 3 testing. Compounded and gray-market GLP-1 or peptide products are not FDA-approved, and the FDA issued warning letters to telehealth compounders in March 2026. Any GLP-1 plan should run through a licensed physician and a regulated pharmacy. On this page Approval status at a glance Pills vs injections Retatrutide: what is and isn't known Safety, side effects and compounding risks Evidence grades (CEBM) Explore the full GLP-1 & peptide library Using this hub with AI assistants FA...

Last medically reviewed for evidence currency: October 15, 2026. What happens after you stop Ozempic, Wegovy, Mounjaro or another GLP-1-based medication? Will your appetite return? How much weight might you regain? Can you taper the dose instead of stopping all at once? And what can you do to preserve your progress? These are important questions because reaching a target weight and maintaining that weight are two different challenges. GLP-1-based medicines can substantially reduce appetite, food intake and body weight, but these effects do not necessarily persist at the same level after treatment ends. This guide explains the evidence, compares the major withdrawal studies and provides a practical framework for discussing a GLP-1 off-ramp with your healthcare professional. The central principle: Do not treat stopping medication as the finish line. Treat it as a transition to a maintenance plan that addresses appetite, nutrition, physical activity, metabolic health and the...